A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE013 (USA) · Dr. Clarke
consented 2023-02-09
Adverse events
Grade 1 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2023-04-04 (study day 42); relationship: N
Grade 1 Vomiting — outcome: RECOVERED/RESOLVED; onset 2023-04-22 (study day 60); relationship: Y
Grade 1 Alopecia — outcome: RECOVERED/RESOLVED; onset 2023-05-08 (study day 76); relationship: not assessed
Grade 1 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-07-28 (study day 157); relationship: not assessed
Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-09-05 (study day 196); relationship: N
Grade 1 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2023-09-19 (study day 210); relationship: N
Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-11-19 (study day 271); relationship: not assessed
Grade 1 Fatigue — outcome: RECOVERED/RESOLVED; onset 2024-01-17 (study day 330); relationship: Y
Data queries
No data queries.